NEU — Neuren Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- AU$2.95bn
- AU$2.66bn
- AU$64.63m
Brief: Neuren Pharmaceuticals Comments On Media Speculation
Australia's Neuren Pharma rise as Jefferies raises PT
Brief: Neuren Pharmaceuticals Says Daybue Net Sales $66.9 Mln In Q3 2023
Australia's Neuren Pharmaceuticals rises on strong sales from US drug licensee
Brief: Neuren Pharmaceuticals Says Cash Generated From Operations In Q3 2023 Was A$135 Mln
Jefferies raises Neuren Pharma's PT citing sales growth in Daybue
Brief: Neuren Pharmaceuticals Posts HY Net Profit Attributable A$47.8 Million
Brief: Neuren Pharmaceuticals Receives Us$100 Mln Initial Payment For Expanded Daybue™ Agreement
Acadia rises as brokerages raise stock PT on Daybue drug sales
Australia's Neuren Pharma rises on expanding license deal with Acadia
Brief: Neuren Pharmaceuticals Acadia Expand Global Partnership For Trofinetide
Acadia Pharma up on licensing agreement for brain disorder drug
Australia's Neuren Pharmaceutical at 17-yr high, gains for fourth straight day
Australia's Neuren Pharmaceuticals hits over 16-year high as partner gets FDA nod
Brief: Neuren Pharmaceuticals Says Acadia Pharmaceuticals Received U.S. FDA Approval Of Daybue
Brief: Neuren Pharmaceuticals Posts FY Profit After Tax A$0.2 Mln Vs Loss A$7.8 Mln
Brief: Neuren Pharmaceuticals Says Prader-Willi Syndrome IND For NNZ-2591 Approved By FDA
Australia's Neuren Pharmaceuticals rises on positive results from Phase 2 drug trials
Australia's Neuren Pharma soars as FDA accepts new drug application for review